CN102805882A - Method for mixing soft tissue filling agent with anesthetic injecta before use - Google Patents
Method for mixing soft tissue filling agent with anesthetic injecta before use Download PDFInfo
- Publication number
- CN102805882A CN102805882A CN2012103096844A CN201210309684A CN102805882A CN 102805882 A CN102805882 A CN 102805882A CN 2012103096844 A CN2012103096844 A CN 2012103096844A CN 201210309684 A CN201210309684 A CN 201210309684A CN 102805882 A CN102805882 A CN 102805882A
- Authority
- CN
- China
- Prior art keywords
- syringe
- fix liquid
- soft tissue
- volume
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000945 filler Substances 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 51
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 42
- 238000002156 mixing Methods 0.000 title claims abstract description 15
- 230000003444 anaesthetic effect Effects 0.000 title description 3
- 238000002347 injection Methods 0.000 claims abstract description 57
- 239000007924 injection Substances 0.000 claims abstract description 57
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 94
- 229940090044 injection Drugs 0.000 claims description 53
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 11
- 229960004194 lidocaine Drugs 0.000 claims description 11
- 229940071643 prefilled syringe Drugs 0.000 claims description 11
- -1 ovocaine Chemical compound 0.000 claims description 8
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 4
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 4
- 229960003150 bupivacaine Drugs 0.000 claims description 4
- 229960003976 etidocaine Drugs 0.000 claims description 4
- SIEYLFHKZGLBNX-NTISSMGPSA-N levobupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-NTISSMGPSA-N 0.000 claims description 4
- 229960002409 mepivacaine Drugs 0.000 claims description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 4
- 229960001807 prilocaine Drugs 0.000 claims description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 229940025300 lidocaine injection Drugs 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 2
- 230000036407 pain Effects 0.000 abstract description 20
- 229940035674 anesthetics Drugs 0.000 abstract description 6
- 239000003193 general anesthetic agent Substances 0.000 abstract description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 229920002674 hyaluronan Polymers 0.000 abstract description 3
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000013112 stability test Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 17
- 230000003796 beauty Effects 0.000 description 9
- 230000003533 narcotic effect Effects 0.000 description 9
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 6
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 241001269238 Data Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a method for mixing soft tissue filling agent with anesthetics injecta before use. The method comprises the following steps of: injecting anesthetics injecta into a prefilling injector filled with soft tissue filling agent by a microsyringe for multiple times, after the anesthetics injecta is injected, stewing for a short time, and then performing even mixing. According to the method, the pain caused by the cosmetic injection can be avoided, the method is high in operability, and is low in technical requirements on operating personnel, and the anesthetics injecta and the soft tissue filling agent can be evenly mixed with each other conveniently and quickly. Compared with the existing method for preparing the preparation by directly adding the anesthetics into hyaluronic acid gel, the method has the advantage of not needing the compatibility test, the stability test and even the clinic test of two drugs under the condition of high-temperature sterilization, so that the method is low in cost. Furthermore, after the mixing is carried out by the method, the soft tissue filling agent is free from the chemical reaction phenomena such as degradation, precipitation, turbidness and the like, so that the method is safe.
Description
Technical field
The present invention relates to a kind ofly will be difficult for two kinds of miscible methods that medicine mixes use before use, be specifically related to a kind of soft tissue filler before use with fix liquid method of mixing.
Background technology
The injection beauty treatment is a kind of of non-operating shaping beauty treatment; Utilize the method for injection that biomaterial or synthetic biocompatible materials are injected into skin corium or subcutaneous, reach the one big type of plastic operation method that reduces skinfold or plastotype through the different mechanism of action.The injection beauty implement need not to perform the operation, advantages such as misery is little, few side effects, instant effect, and the market demand constantly enlarges.
Along with the injection beautifying technique is more and more flourishing, injection beauty treatment crowd is more and more growth also.In exploitation injection cosmetics; Injection beauty treatment person self experiences the factor that also becomes doctor and manufacturer consideration gradually; When injection hyaluronic acid derivatives filler product, the puzzlement that distending pain that pain on injection and injection back filler cause in vivo and sense of discomfort become numerous beauty treatment persons.In order to reduce or reduce patient's misery, to being carried out anaesthetic treatment, following anesthesia is arranged at present usually by the injector:
1, topical anesthesia: anesthesia unguentum such as lignocaine are applied to skin to be injected place, disinfect in alcohol behind the 30-60 min.The method can only be eliminated the pain that causes in the injection process, and the distending pain that filler is caused is invalid.
2, anesthesia injection: injecting anesthetic remover liquid injection, the method also only can be eliminated the pain that causes in the injection filler process, and the distending pain that filler is caused is invalid, and injected with lidocaine also can be brought pain.
3, anesthetis is mixed process compositions in the hyaluronic acid; Thereby thoroughly solve injection pain and filler swelling pain problem; Had a lot of producers that anesthetis such as lignocaine are joined in the filler at present, related patent U.S. Patent No. has CN200980139162.0 (comprising narcotic hyalomitome acidic group gel), CN200980139163.5 (comprising narcotic hyalomitome acidic group gel), CN200880115067.2 (anesthetics compositions, preparation and method for using).Directly admixture anesthetis can be removed the pain of injection and the pain of filling back swelling simultaneously in implant, removes the pain that injection brings to the patient.
Summary of the invention
The present invention is directed to above deficiency; Provide a kind of soft tissue filler before use with fix liquid method of mixing, this method can be before injection with fix liquid and soft tissue filler mix homogeneously in the short period of time, thereby all pain of being brought with the injection back can eliminate injection simultaneously the time; Remove patient's pain; And this method is convenient, fast, need not by special equipment and condition, can not increase the financial burden of user.
The present invention realizes through following measure:
A kind of soft tissue filler before use with fix liquid method of mixing; Said soft tissue filler includes but not limited to hyalomitome acids soft tissue filler (the hyalomitome acids comprises hyaluronic acid or its salt), and said fix liquid is one or more in lignocaine, procaine, ovocaine, prilocaine, bupivacaine, mepivacaine, Carbocainum, etidocaine and the chirocaine injection; Fix liquid is injected soft tissue filler several times, and fix liquid injects the diverse location of soft tissue filler at every turn.It is mix homogeneously that the gained mixture leaves standstill a period of time, and this time is about 5-10 min.
Concrete, mixed method of the present invention may further comprise the steps:
(1) gets in the prefilled syringe that soft tissue filler is housed (being called for short syringe, down together) of sterilization, move behind the catch bar with syringe to make and vacate the space that holds fix liquid in the syringe;
(2) microsyringe with sterilization extracts fix liquid, and is subsequent use;
(3) the soft tissue filler volume is designated as V1, fix liquid is divided into X part, divide and inject syringe X time; Method for implanting is following: at first; The syringe needle of microsyringe is penetrated the bottom until soft tissue filler from the head of syringe, in syringe, inject the fix liquid of a volume, the syringe needle with microsyringe (also is the injector head direction to the injector cephalad direction then; Down with) retreat the distance of V1/X volume; In syringe, inject the fix liquid of a volume again, continue the syringe needle of microsyringe is retreated the distance of V1/X volume to the injector cephalad direction, and then in syringe, inject the fix liquid of a volume; The step that microsyringe repeatedly like this is retreated and injected is all injected syringe until fix liquid;
(4) after fix liquid all injects syringe,, can use at aseptic, normal temperature environment held 5-10 min with the syringe horizontal positioned.
In the above-mentioned mixed method; Fix liquid divides the injection syringe 5-10 time; The number of times that divides many fix liquid more is short more with the time of filler mix homogeneously, also not have too big necessity, 10 injections of a therefore preferred branch syringe but the each volume that injects of fix liquid is too small.
In the above-mentioned mixed method, preferably fix liquid is equally divided into X part, the volume of so each injection syringe is identical.Fix liquid is divided equally back not dividing equally than it with the incorporation time of filler mix weak point, general 5-10 min is a mix homogeneously.
Used anesthetis, narcotic concentration, the narcotic kind of the present invention all belongs to prior art, and those skilled in the art can obtain from prior art.For example; The volume ratio of fix liquid and soft tissue filler adopts the general proportionate relationship of using in the prior art; General volume ratio is 1:5 ~ 1:20; Narcotic concentration (w/w) is generally 0.05%～0.5% in the fix liquid, and used fix liquid can be in lignocaine, procaine, ovocaine, prilocaine, bupivacaine, mepivacaine, Carbocainum, etidocaine and the chirocaine injection one or more, preferred lidocaine injection.
The pain that causes during for fear of the injection beauty treatment; The invention provides a kind of soft tissue filler before use with fix liquid method of mixing; This method is workable; To operator technical require low, can be easy, quickly with fix liquid and soft tissue filler mix homogeneously, fix liquid directly added the method for processing preparation in the hyaluronic acid derivatives compare with disclosed now; Needn't do compatibility experiment, stability experiment even the clinical trial of two kinds of medicines under the high temperature sterilize condition; Cost is low and adopt this method mixing back soft tissue filler can not degrade, and also chemical reaction phenomenons such as deposition, muddiness can not occur, is safe method.
Description of drawings
Fig. 1 for the present invention with soft tissue filler before use with the blended sketch map of fix liquid.
Among the figure, 1, prefilled syringe, 2, catch bar, 3, soft tissue filler, 4, vacant position, 5, microsyringe, 6, fix liquid, 7, syringe needle.
The specific embodiment
The preceding soft tissue filler of the suitable beauty treatment injection of method of the present invention mixes with fix liquid, below in conjunction with Fig. 1 mixed method of the present invention is carried out detailed explanation.
As shown in Figure 1; Prefilled syringe 1 (is called for short syringe; Soft tissue filler (being called for short filler, down together) 3 is housed down together), fix liquid 6 is housed in the microsyringe 5; This fix liquid reaches the purpose of when injection, the patient fully being anaesthetized in strict accordance with the consumption metering of filler.Fix liquid is injected filler several times; Fix liquid injects the diverse location of soft tissue filler at every turn; Fix liquid is dispersed in the diverse location of filler; Like this can be faster and the filler mix homogeneously, the liquid of fix simultaneously adds several times, has prevented once to add problems such as causing bubble and has occurred.
Following mask body is introduced mixed method of the present invention, in order to express easily, the filler volume is designated as V1, and the volume of fix liquid is designated as V2, and fix liquid injects syringe several times, and the injection number of times of fix liquid is designated as X.Before mixing beginning; Elder generation is with the catch bar 2 slow astern segment distances of syringe 1; Make injector head vacate a part of vacant position 4, so that hold the volume of fix liquid, the volume of vacant position preferably equates or is slightly larger than the volume of anesthesia liquid with the volume of fix liquid; Have scale on the syringe, can accurately retreat certain distance according to top scale.After moving behind the catch bar, the syringe needle 7 of microsyringe is penetrated the bottom (being the end position of catch bar) until soft tissue filler from the head of syringe.Fix liquid divides the injection syringe X time; Therefore fix liquid cumulative volume is divided into X part; Therefore each portion that injects X part preferably is divided into X part with fix liquid, and each volume that injects is preferably V2/X; Have scale on the microsyringe, can inject the fix liquid of setting volume accurately according to scale during injection.
Mixed method of the present invention is not with the disposable injection implant of fix liquid, is difficult to mix homogeneously like this, and is easy to generate the difficult injection of bubble.Key problem in technology of the present invention is that fix liquid is divided into different umbers; Filler also is divided into same umber; Every part of fix liquid is injected every part of soft tissue filler that is arranged in diverse location respectively; Fix liquid and filler can be mixed evenly fast, and be difficult for producing bubble.
Be the committed step of mixed method of the present invention below: after the syringe needle of microsyringe is inserted to the bottom of soft tissue filler; In syringe, inject a fix liquid of X part (the fix liquid of preferred V2/X volume); Then the syringe needle of microsyringe is retreated the distance of V1/X volume to the injector head position; In syringe, inject the fix liquid liquid (the fix liquid of preferred V2/X volume) of a volume again; The distance of V1/X volume is retreated the syringe needle of microsyringe in continuation to the injector head position; And then in syringe, inject the fix liquid liquid (the fix liquid of preferred V2/X volume) of a volume, the microsyringe step retreating and inject is all injected syringe until fix liquid so repeatedly.After fix liquid all injects syringe; With syringe under aseptic, normal temperature environment, horizontal positioned, fix liquid is further mixed naturally, through a large amount of experimental datas statistics with filler; Leave standstill that fix liquid and filler are mix homogeneously behind the 5-10 min; Behind the mix homogeneously, set up aseptic syringe needle, can inject use in injector head.
In theory, the number of times that fix liquid injects is many more, and the umber that filler is divided into is also many more; Mix quick more, but consider and operability generally fix liquid be divided into 5-10 part; Be divided into 5-10 injection syringe and get final product, be i.e. X=5-10, preferably X=10.
Generally; The used fix liquid of beauty industry comprises but is not limited to lignocaine, procaine, ovocaine, prilocaine, bupivacaine, mepivacaine, Carbocainum, etidocaine, chirocaine injection etc.; Fix liquid of the present invention can be a kind of in these; Also can be the mixture of the multiple composition in them, preferred lidocaine injection.
General, narcotic concentration (w/w) is 0.05%～0.5% in the fix liquid, can in market now, be chosen in the product of this concentration range; According to required narcotic amount; Fix liquid concentration is big, and employed volume is just smaller relatively, and fix liquid concentration is little; Employed volume is just big; When the present invention mixes used anesthetis and bulking of soft tissue adopt this area consumption commonly used with magnitude relation, be generally fix liquid: the volume ratio of soft tissue filler is 1:5 ~ 1:20, in the specific implementation; The volume ratio that can select fix liquid and soft tissue filler is the arbitrary value in the scope for this reason, for example 1:5,1:10,1:15,1:20 etc.According to narcotic consumption, can select the fix liquid of suitable concn, suitable volumes to mix with implant.And can be according to the big or small parameters such as injection number of times of confirming fix liquid of the volume of fix liquid.
Be example with the benefit caine below; Enumerate preferred embodiment of the present invention, used soft tissue filler commodity profit by name hundred face, general injection by name is modified hyaluronic acid sodium gel (abbreviation gel); Concentration is 1ml:20mg, is produced by China's prosperous Fu Ruida biological medicine company limited; Used lignocaine is the lidocaine hydrochloride injection of concentration (w/w) 0.2%, is produced by Shangdong Hualu Pharmaceutical Co., Ltd..
Embodiment
Get the prefilled syringe that the injection hyaluronic acid sodium gel is housed, 1 ml gel is housed in the prefilled syringe body, extracting 0.1 ml concentration (w/w) with microsyringe is 0.2% lidocaine hydrochloride injection.The catch bar of prefilled syringe is retreated about 0.1 ml; The syringe needle of microsyringe is inserted into the bottom of gel, injects 10 μ l lidocaine hydrochloride injections, then the syringe needle of microsyringe is retreated the distance of 0.1 ml to the prefilled syringe cephalad direction; 10 μ l lidocaine hydrochloride injections reinject; The operation that lidocaine hydrochloride injection was retreated and injected to microsyringe repeatedly like this is all injected prefilled syringe until lidocaine hydrochloride, and injecting number of times is 10 times.
After the mixing,, under aseptic, normal temperature environment, leave standstill 5-10 min, do not have phenomenons such as muddiness, deposition and occur the prefilled syringe horizontal positioned, place 12 h after, the lamp inspection observation is with dosing liquid product there was no significant difference not.
This method is mixed the fix liquid of gained and the mixture of filler carries out clinical trial among a small circle, and the test number is 8 people, male 4 people, and women 4 people, the age, the mean age was 38.4 years old between 20-50 year, all experimenter's healths are all healthy.Before injection, adopt the inventive method in advance lignocaine to be sneaked into injection and modify in the hyaluronic acid sodium gel, leave standstill 10 min, set up aseptic syringe needle in injector head then, injection is modified hyaluronic acid sodium gel inject experimenter's nasolabial fold wrinkle.One side is modified hyaluronic acid sodium gel with the injection of mixing lignocaine, and opposite side is modified hyaluronic acid sodium gel with the conventional narcotic injection that do not contain.The experimenter self is felt as injection: compare with the product of Caledonia caine not, the product that adds lignocaine can significantly alleviate the distending pain after pain on injection and the injection etc., and the ametaboly reaction of injection back or other untoward reaction take place.Simultaneously, experimenter's light pain of Caledonia caine has reduced the side reaction after the injection.The explanation of this phenomenon, the inventive method can be with fix liquid and the abundant mix homogeneously of filler, and safe in utilization, and the pain of having exempted user has alleviated the fear of user, reduction postoperative rate of side effects.
Claims (7)
- A soft tissue filler before use with fix liquid method of mixing; It is characterized by said soft tissue filler and include but not limited to hyalomitome acids soft tissue filler, said fix liquid is one or more in lignocaine, procaine, ovocaine, prilocaine, bupivacaine, mepivacaine, Carbocainum, etidocaine and the chirocaine injection; Fix liquid is injected soft tissue filler several times, and fix liquid injects the diverse location of soft tissue filler at every turn.
- 2. method according to claim 1 is characterized in that mixing may further comprise the steps:(1) gets the prefilled syringe that soft tissue filler is housed, move behind the catch bar with prefilled syringe to make and vacate the space that holds fix liquid in the syringe;(2) microsyringe with sterilization extracts fix liquid, and is subsequent use;(3) the soft tissue filler volume is designated as V1; Fix liquid is divided into X part, divides and inject syringe X time, method for implanting is following: at first; The syringe needle of microsyringe is penetrated the bottom until soft tissue filler from the head of syringe; In syringe, inject the fix liquid of a volume, then the syringe needle of microsyringe is retreated the distance of V1/X volume to the injector cephalad direction, in syringe, inject the fix liquid of a volume again; The distance of V1/X volume is retreated the syringe needle of microsyringe in continuation to the injector cephalad direction; And then in syringe, inject the fix liquid of a volume, the microsyringe step retreating and inject is all injected syringe until fix liquid so repeatedly;(4) after fix liquid all injects syringe,, can use at aseptic, normal temperature environment held 5-10 min with the syringe horizontal positioned.
- 3. method according to claim 1 and 2 is characterized in that: fix liquid divides the injection syringe 5-10 time.
- 4. method according to claim 3 is characterized in that: fix liquid divides the injection syringe 10 times.
- 5. method according to claim 2 is characterized in that: fix liquid is divided into X part, and the volume that at every turn injects syringe is identical.
- 6. method according to claim 1 and 2 is characterized in that: the volume ratio of fix liquid and soft tissue filler is 1:5 ~ 1:20.
- 7. method according to claim 1 and 2 is characterized in that: said fix liquid is lidocaine injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210309684.4A CN102805882B (en) | 2012-08-28 | 2012-08-28 | Method for mixing soft tissue filling agent with anesthetic injecta before use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210309684.4A CN102805882B (en) | 2012-08-28 | 2012-08-28 | Method for mixing soft tissue filling agent with anesthetic injecta before use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102805882A true CN102805882A (en) | 2012-12-05 |
| CN102805882B CN102805882B (en) | 2014-04-23 |
Family
ID=47229864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210309684.4A Active CN102805882B (en) | 2012-08-28 | 2012-08-28 | Method for mixing soft tissue filling agent with anesthetic injecta before use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102805882B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3015290A1 (en) * | 2013-12-23 | 2015-06-26 | Vivacy Lab | HYALURONIC ACID COMPOSITIONS COMPRISING MEPIVACAINE |
| US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
| CN111787966A (en) * | 2017-12-19 | 2020-10-16 | 大化制药株式会社 | Method for manufacturing a prefilled syringe comprising a local anesthetic and a hyaluronic acid hydrogel |
| CN113546539A (en) * | 2020-04-24 | 2021-10-26 | 透策生技股份有限公司 | Treatment method for accelerating dispersion of injection filler by using pressurization means |
| CN113648459A (en) * | 2013-07-30 | 2021-11-16 | 泰奥赛恩公司 | Composition comprising hyaluronic acid and mepivacaine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4243080A (en) * | 1977-10-06 | 1981-01-06 | American Hospital Supply Corporation | Method of mixing plural components |
| US4254768A (en) * | 1979-09-14 | 1981-03-10 | Ty Perla J | Hypodermic syringe |
| US4743229A (en) * | 1986-09-29 | 1988-05-10 | Collagen Corporation | Collagen/mineral mixing device and method |
| CN101027065A (en) * | 2004-06-15 | 2007-08-29 | 陈献 | Phospholipid compositions and methods for their preparation and use |
-
2012
- 2012-08-28 CN CN201210309684.4A patent/CN102805882B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4243080A (en) * | 1977-10-06 | 1981-01-06 | American Hospital Supply Corporation | Method of mixing plural components |
| US4254768A (en) * | 1979-09-14 | 1981-03-10 | Ty Perla J | Hypodermic syringe |
| US4743229A (en) * | 1986-09-29 | 1988-05-10 | Collagen Corporation | Collagen/mineral mixing device and method |
| CN101027065A (en) * | 2004-06-15 | 2007-08-29 | 陈献 | Phospholipid compositions and methods for their preparation and use |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113648459A (en) * | 2013-07-30 | 2021-11-16 | 泰奥赛恩公司 | Composition comprising hyaluronic acid and mepivacaine |
| FR3015290A1 (en) * | 2013-12-23 | 2015-06-26 | Vivacy Lab | HYALURONIC ACID COMPOSITIONS COMPRISING MEPIVACAINE |
| WO2015097261A1 (en) * | 2013-12-23 | 2015-07-02 | Laboratoires Vivacy | Hyaluronic acid compositions including mepivacaine |
| JP2017500358A (en) * | 2013-12-23 | 2017-01-05 | ラボラトアール ヴィヴァシィ | Hyaluronic acid composition containing mepivacaine |
| EP3173086A1 (en) | 2013-12-23 | 2017-05-31 | Laboratoires Vivacy | Hyaluronic acid compositions including mepivacaine |
| FR3044228A1 (en) * | 2013-12-23 | 2017-06-02 | Lab Vivacy | HYALURONIC ACID COMPOSITIONS COMPRISING MEPIVACAINE |
| EA031349B1 (en) * | 2013-12-23 | 2018-12-28 | Лаборатуар Виваси | Hyaluronic acid composition including mepivacaine |
| EA036502B1 (en) * | 2013-12-23 | 2020-11-17 | Лаборатуар Виваси | Hyaluronic acid compositions including mepivacaine |
| EP3799875A1 (en) * | 2013-12-23 | 2021-04-07 | Laboratoires Vivacy | Hyaluronic acid compositions including mepivacaine |
| US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
| CN111787966A (en) * | 2017-12-19 | 2020-10-16 | 大化制药株式会社 | Method for manufacturing a prefilled syringe comprising a local anesthetic and a hyaluronic acid hydrogel |
| CN113546539A (en) * | 2020-04-24 | 2021-10-26 | 透策生技股份有限公司 | Treatment method for accelerating dispersion of injection filler by using pressurization means |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102805882B (en) | 2014-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goldie et al. | Global consensus guidelines for the injection of diluted and hyperdiluted calcium hydroxylapatite for skin tightening | |
| CN102805882B (en) | Method for mixing soft tissue filling agent with anesthetic injecta before use | |
| US8142817B2 (en) | Composition for restoration of age related tissue loss in the face or selected areas of the body | |
| Romagnoli et al. | Hyaluronic acid–based fillers: theory and practice | |
| BR112015031026B1 (en) | method for crosslinking hyaluronic acid or one of its salts or other biocompatible polymers; method for preparing an injectable hydrogel; hydrogel; kit and use | |
| CN102724951A (en) | Compositions and methods for stimulating hair growth | |
| CN105748315B (en) | A kind of composition for repairing skin barrier | |
| Daumas et al. | Fat grafting for treatment of facial scleroderma | |
| WO1993002699A1 (en) | Use of collagen for the treatment of degenerative joint ailments | |
| Vedamurthy | Soft tissue augmentation-Use of hyaluronic acid as dermal filler | |
| CN106176758B (en) | A kind of externally-applied medicinal composition | |
| AU2018290765A1 (en) | Clostridial neurotoxin formulations and use | |
| ATE298256T1 (en) | BIOMATERIAL IN THE FORM OF MICROPARTICLES OF HYALURONIC ACID FOR MEDICAL USE | |
| CN110151687A (en) | A kind of stable chloraldurate solution and its preparation method and application | |
| CA2496121A1 (en) | Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy | |
| Van Loghem | Use of calcium hydroxylapatite for augmentation of the labia majora and mons pubis | |
| CN100443078C (en) | Gel for local anesthesia and analgesia on surface of skin, and usage | |
| Coimbra et al. | Injectable Poly-L-Lactic Acid for the Arms | |
| KR20090011604U (en) | pain free intra-articular injection | |
| YUTSKOVSKAYA et al. | Neck and chest | |
| CN105878427A (en) | Peony seed oil compound spray for curing burn and scald and preparation method | |
| Yutskovskaya et al. | Neck and chest: MesoCaHA for cheeks, neck, and décolletage | |
| CN107441553B (en) | Preparation method of beauty implant | |
| CN101011456A (en) | Externally used antiphlogistic anti-allergic medicament stilbene pine cream for skin side effect of cortical hormone | |
| RU2659959C1 (en) | Composition of the preparation for correction of skin defects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING BLOOMAGE HYINC TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BLOOMAGE FREDA BIOPHARM CO., LTD. Effective date: 20140605 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 100022 CHAOYANG, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140605 Address after: 100022, Beijing, Chaoyang District, No. 6, No. 23, D, block 3, World Trade Center, Central Patentee after: BEIJING HUAXI HAIYU TECHNOLOGY CO.,LTD. Address before: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Patentee before: BLOOMAGE FREDA BIOPHARM Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20190724 Address after: 250101 high tech Zone, Shandong, Ji'nan Century Avenue, No. 3333 Patentee after: SHANDONG BLOOMAGE HYINC BIOPHARM Corp.,Ltd. Address before: 100022, Beijing, Chaoyang District, No. 6, No. 23, D, block 3, World Trade Center, Central Patentee before: BEIJING HUAXI HAIYU TECHNOLOGY CO.,LTD. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230620 Address after: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Patentee after: BLOOMAGE BIOTECH Co.,Ltd. Address before: 250101 No. 3333, Century Avenue, high tech Zone, Ji'nan, Shandong Patentee before: SHANDONG BLOOMAGE HYINC BIOPHARM Corp.,Ltd. |
|
| TR01 | Transfer of patent right |